销售模式优化
Search documents
柳钢股份:公司持续优化销售模式,优先保障直供终端与重点工程订单
Zheng Quan Ri Bao Wang· 2025-11-04 13:42
Core Viewpoint - LiuGong Co., Ltd. (601003) has achieved over 50% direct sales ratio for steel products this year, indicating a strategic shift towards optimizing sales models and enhancing customer-centric approaches [1] Group 1: Sales Strategy - The company prioritizes direct supply to end-users and key engineering projects, reflecting a transformation in its operational philosophy [1] - LiuGong aims to provide diversified solutions based on customer needs, enhancing its service offerings [1] Group 2: Market Expansion - The company is deepening regional collaboration to improve rapid supply and service response capabilities [1] - LiuGong is focusing on core end customers and seizing policy opportunities to tap into potential markets [1] Group 3: Product Development - The company plans to strengthen research efforts to explore steel demand across multiple sectors [1] - LiuGong intends to expand its market for high-margin products, aiming to increase market share and competitiveness in niche areas [1]
证券代码:603367 证券简称:辰欣药业 公告编号:2025-049
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-09-02 23:37
Group 1 - The company held a half-year performance and cash dividend briefing on September 2, 2025, attended by key executives including the chairman and financial director [1][2]. - The company reported a revenue of 3,981,572,232.95 yuan for 2024, a decrease of 10.77% compared to 2023's revenue of 4,462,348,636.07 yuan [4]. - For the first half of 2025, the company achieved a revenue of 1.74 billion yuan, a decrease of 15.97% year-on-year, with a net profit attributable to shareholders of 229 million yuan, down 15.23% [6]. Group 2 - The company aims to enhance its core competitiveness through innovation and quality, focusing on high-quality development and optimizing its product mix to meet market demands [2][3]. - The company has over 100 ongoing research projects, targeting various therapeutic areas including oncology and cardiovascular diseases, to build a complementary product portfolio [5]. - The company emphasizes a diversified sales model, leveraging both policy responsiveness and resource integration to maintain revenue and profit sustainability amid industry price pressures [6][7]. Group 3 - The company has implemented a comprehensive employee training program to ensure high-quality development, focusing on talent cultivation and management [7]. - The company has established an audit committee for internal control and risk management, ensuring effective oversight of its subsidiaries [8]. - The company's 2020 equity incentive plan has been fully implemented [9].